U.S. Stem Cell, Inc. (USRM)
|Net Income (ttm)||-3.29M|
|Trading Day||July 26|
|Day's Range||0.0093 - 0.0100|
|52-Week Range||0.0033 - 0.0870|
There are no news available yet.
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell ... [Read more...]
|IPO Date |
Feb 15, 2008
|Stock Exchange |
|Ticker Symbol |
In 2020, U.S. Stem Cell's revenue was $277,087, a decrease of -90.98% compared to the previous year's $3.07 million. Losses were -$2.89 million, -24.64% less than in 2019.